India's second largest drugmaker by sales, Dr Reddy’s Laboratories (NYSE: RDY), yesterday announced its unaudited consolidated financial results for the quarter ended September 30, 2012, with consolidated revenues growing 27% to 28.8 billion rupees ($536.6 million), beating consensus forecasts of 27.83 billion rupees.
EBITDA for the quarter was 7.7 billion rupees, 27% of revenues, and year-on-year growth of 47%. Profit after tax came in at 4.07 billion rupees, which was better than a consensus of 3.73 billion rupees, according Thomson Reuters I/B/E/S. Dr Reddy’s shares rose 2% to 1,729.95 rupees in morning trading on the Bombay Stock Exchange following release of the figures.
Segmental analysis
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze